Studies on semicarbazide-sensitive amine oxidase in patients with diabetes mellitus and in transgenic mice.
Patients with diabetes mellitus and with vascular complications in particular, exhibit higher plasma activities of semicarbazide-sensitive amine oxidase (SSAO) compared to control subjects. It has been speculated that production of cytotoxic products of SSAO may cause endothelial damage and thus contribute to the development of diabetic vascular complications such as retino-, nephro-, and neuropathies as a result of SSAO activity.In order to explore the possibility that high SSAO activity contributes to the development of vascular complications in diabetes, we have performed two studies in patients with Type-2 diabetes quantifying plasma SSAO activity, HbA(1c), and urinary levels of the SSAO substrate, methylamine. We also examined the prevalence of retinopathy in these patients. Additionally, we have studied a model of transgenic mice expressing human SSAO in smooth muscle cells. The transgenic mice have an increased SSAO activity as well as mRNA expression. Histological studies revealed a specific aorta phenotype with a condensed and rigid vessel wall in some of the transgenic mice. No wild-type animals displayed this phenotype.In conclusion, we suggest that this transgenic mouse model may be of great value for increasing the knowledge about to what extent human SSAO contributes to vascular complications in diabetes, and also to which extent inhibition of SSAO can prevent the development of such complications.
Göktürk
C
C
Department of Neuroscience, Unit of Pharmacology, Uppsala University, P.O. Box 593, SE-751 24 Uppsala, Sweden. Camilla.Gokturk@neuro.uu.se
Garpenstrand
H
H
Nilsson
J
J
Nordquist
J
J
Oreland
L
L
Forsberg-Nilsson
K
K
D006631:Amine Oxidase (Copper-Containing) / Q000097:blood* / Q000235:genetics; D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000201:enzymology*; D003930:Diabetic Retinopathy / Q000201:enzymology*; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D012663:Semicarbazides / Q000494:pharmacology*
D012663:Semicarbazides; D006631:Amine Oxidase (Copper-Containing)